» Articles » PMID: 12198243

The Small Heterodimer Partner Interacts with the Liver X Receptor Alpha and Represses Its Transcriptional Activity

Overview
Journal Mol Endocrinol
Date 2002 Aug 29
PMID 12198243
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

The small heterodimer partner SHP (NR0B2) is an unusual nuclear receptor that lacks the typical DNA binding domain common to most nuclear receptors. SHP has been reported to act as a corepressor for several nuclear receptors, but its exact mechanism of action is still elusive. Here we show that SHP can interact with the liver X receptors LXRalpha (NR1H3) and LXRbeta (NR1H2), as demonstrated by glutathione-S-transferase pull-down assays, mammalian two-hybrid, and coimmunoprecipitation experiments. In transfection assays, SHP inhibits the expression of an artificial reporter driven by an LXR-response element and represses the transcriptional activation by LXR of the human ATP-binding cassette transporter 1 (ABCA1) promoter. Treatment of Caco-2 cells with bile acids, which activate farnesoid X receptor and subsequently induce SHP, leads to the repression of the human ABCG1 gene, an established LXR target gene. These results demonstrate that SHP is able to interact with LXR and to modulate its transcriptional activity.

Citing Articles

Damaging mutations in liver X receptor-α are hepatotoxic and implicate cholesterol sensing in liver health.

Lockhart S, Muso M, Zvetkova I, Lam B, Ferrari A, Schoenmakers E Nat Metab. 2024; 6(10):1922-1938.

PMID: 39322746 PMC: 11496107. DOI: 10.1038/s42255-024-01126-4.


Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells.

Vidana Gamage H, Albright S, Smith A, Farmer R, Shahoei S, Wang Y Cancer Lett. 2024; 597:217086.

PMID: 38944231 PMC: 11890212. DOI: 10.1016/j.canlet.2024.217086.


NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors.

Vidana Gamage H, Shahoei S, Wang Y, Jacquin E, Weisser E, Bautista R Cancer Lett. 2024; 597:217042.

PMID: 38908543 PMC: 11892351. DOI: 10.1016/j.canlet.2024.217042.


Assessing causal associations of bile acids with obesity indicators: A Mendelian randomization study.

Huang C, Xu S, Chen R, Ding Y, Fu Q, He B Medicine (Baltimore). 2024; 103(25):e38610.

PMID: 38905395 PMC: 11191951. DOI: 10.1097/MD.0000000000038610.


Bile acid metabolism and signaling: Emerging pharmacological targets of dietary polyphenols.

Tveter K, Mezhibovsky E, Wu Y, Roopchand D Pharmacol Ther. 2023; 248:108457.

PMID: 37268113 PMC: 10528343. DOI: 10.1016/j.pharmthera.2023.108457.